📄 medicine

Characterization of pharmacological inhibition of the hERG potassium channel by nitazene opioids

This study demonstrates that nitazene opioids directly inhibit the hERG potassium channel through a voltage- and time-dependent gating mechanism involving specific aromatic residues, thereby posing a significant risk of cardiac arrhythmia.

Original authors: Monisha R Chowdhury, Matteo Baque, Thomas Osborne, Hongwei Cheng, Oliver Hannington, Yihong Zhang, Aziza El Harchi, Caroline Copeland, Robin A Corey, Stephen C Harmer, Jules Hancox

Published 2026-10-21

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Monisha R Chowdhury, Matteo Baque, Thomas Osborne, Hongwei Cheng, Oliver Hannington, Yihong Zhang, Aziza El Harchi, Caroline Copeland, Robin A Corey, Stephen C Harmer, Jules Hancox

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The human heart relies on a precise electrical rhythm to pump blood, a rhythm maintained by tiny molecular gates in the heart cell walls that open and close to let charged particles flow. Among these gates, one specific type, known as the hERG channel, acts as a critical brake that helps the heart reset after each beat. When this channel is blocked by certain medications or substances, the heart's electrical reset is delayed, which can lead to a dangerous irregularity in rhythm. While doctors have long known that some prescription drugs can accidentally jam this channel, a new and growing threat has emerged from the illicit drug market: a family of synthetic opioids called nitazenes. These substances, often sold on the street as alternatives to heroin, are known to cause fatal breathing problems, but scientists had not yet determined if they also pose a direct risk to the heart's electrical system.

Researchers at the University of Bristol and other institutions set out to answer this question by testing five different nitazene compounds, including isotonitazene and protonitazene, on human heart cells grown in a laboratory. Using a technique that allows them to measure the tiny electrical currents flowing through the heart cell channels, the team discovered that all five of these drugs act as powerful blockers of the hERG channel. The study found that even at very low concentrations, these substances could significantly reduce the flow of electrical current, with some blocking the channel more effectively than well-known heart medications. The researchers observed that the drugs did not simply sit on the surface of the channel; instead, they seemed to enter the channel's pore and get stuck there, particularly when the channel was in the process of opening or closing. This behavior suggests that the drugs physically interfere with the channel's ability to function, rather than causing the heart cells to stop making the channels altogether.

To understand exactly how these drugs bind to the channel, the scientists looked at the specific molecular shapes of the channel's interior. They found that the drugs latch onto specific aromatic amino acid residues, which act like sticky landing pads inside the channel. One particular landing pad, a residue called F656, appeared to be especially important; when the researchers altered this spot in the channel, the drugs lost much of their ability to block the current. Computer simulations of the drugs inside the channel confirmed this physical interaction, showing the molecules fitting into the channel's inner cavity and touching these key residues. The study also revealed that the risk of this blockage changes depending on the chemical environment of the blood. For one of the drugs, isotonitazene, the blocking effect became significantly stronger if the level of potassium in the surrounding fluid dropped, a condition known as hypokalemia that can occur during drug overdose or illness. This suggests that the danger of heart rhythm problems from this specific drug could be much higher in a person with low potassium levels.

The researchers also tested what happens when these nitazenes are mixed with other common illicit drugs, such as fentanyl. They found that combining the drugs made the blockage of the heart channel worse than if either drug were taken alone. This additive effect means that the risk of a fatal heart rhythm disturbance increases when these substances are used together, a scenario that is unfortunately common in the current drug crisis. The study did not find that these drugs caused the heart cells to stop producing the channels over time, indicating that the danger comes from the immediate, acute presence of the drug in the system rather than long-term damage to the cell's ability to make the channels.

These findings provide the first direct experimental proof that nitazene opioids can directly interfere with the heart's electrical reset mechanism. While the primary danger of these drugs is widely recognized as respiratory failure, this research adds a critical new layer of risk: the potential for sudden cardiac arrest due to electrical disruption. The study highlights that the potency of this effect varies between different nitazene compounds and can be influenced by the user's electrolyte balance and the presence of other drugs. By identifying the specific molecular targets and conditions that make these drugs dangerous to the heart, the research offers a clearer picture of the full scope of the threat posed by these potent synthetic opioids.

Technical Summary: Characterization of Pharmacological Inhibition of the hERG Potassium Channel by Nitazene Opioids

Problem Statement
Nitazene opioids are a class of synthetic $\mu$ -opioid receptor agonists that have emerged as a significant threat in the global opioid crisis, often surpassing heroin in potency and causing fatal respiratory depression. While their primary acute risk is respiratory failure, emerging evidence suggests potential cardiotoxicity, including cardiac arrest. Previous machine learning models predicted that several nitazenes (specifically isotonitazene, protonitazene, etonitazene, metonitazene, and brorphine) might interact with the human ether-à-go-go Related Gene (hERG) potassium channel. Inhibition of hERG, which underpins the rapid delayed rectifier potassium current ( $I_{Kr}$ ), is a major cause of acquired Long QT Syndrome (LQTS) and the associated arrhythmia, torsades de pointes (TdP). However, prior to this study, no experimental in vitro data existed to confirm whether nitazenes directly inhibit hERG channels or to elucidate the mechanistic basis of such interactions.

Methodology
The study utilized automated patch-clamp electrophysiology on HEK293 cells stably expressing wild-type (WT) hERG channels and various mutants.

Compounds Tested: Isotonitazene, protonitazene, etonitazene, metonitazene, and brorphine. Isotonitazene and protonitazene were selected for detailed mechanistic analysis.
Electrophysiological Protocols: Standard voltage-clamp protocols were used to elicit $I_{hERG}$ tail currents. Concentration-response relationships were established to determine half-maximal inhibitory concentrations ( $IC_{50}$ ).
Mechanistic Probes:
- Voltage and Time Dependence: Envelope-of-tails protocols and varying test potentials were used to assess gating dependence.
- Mutagenesis: The study employed the N588K mutation (which attenuates channel inactivation) and aromatic residue mutations in the S5 and S6 transmembrane segments (F557L, Y652A, F656A) to map the binding site.
- Trafficking Assays: Chronic exposure experiments were conducted to determine if nitazenes reduced hERG surface expression.
- Environmental Factors: Experiments were performed under hypokalemic conditions (1 mM $[K^+]_o$ ) and in combination with fentanyl to assess risk factors.
- Computational Modeling: In silico molecular docking (using GNINA/AutoDock Vina) and molecular dynamics (MD) simulations were performed to visualize ligand binding poses and calculate binding free energies.

Key Results

Direct Inhibition: All five tested nitazene compounds (isotonitazene, protonitazene, etonitazene, metonitazene, and brorphine) produced acute, concentration-dependent inhibition of $I_{hERG}$ . The $IC_{50}$ values ranged from 0.5 $\mu$ M (protonitazene) to 1.32 $\mu$ M (isotonitazene), placing them in a potency range comparable to or exceeding the Class Ia antiarrhythmic drug quinidine ( $IC_{50}$ 1.27 $\mu$ M).
Gating Dependence: Inhibition was voltage- and time-dependent. The block developed progressively during depolarization, and there was no evidence of closed-state inhibition. This indicates a gating-dependent mechanism where the channel must open (and likely inactivate) for the drug to bind.
Role of Inactivation: The N588K mutation, which impairs inactivation, significantly reduced drug potency. The $IC_{50}$ for isotonitazene increased 5.1-fold, and for protonitazene 3.3-fold, compared to WT. This suggests that intact inactivation gating facilitates optimal drug binding, though the effect is less profound than for high-affinity blockers like E-4031.
Binding Site Mapping: Mutations of canonical aromatic pore residues (F557, Y652, F656) significantly reduced inhibition.
- F557L and Y652A: Both mutations reduced potency by approximately 7–8 fold for both isotonitazene and protonitazene.
- F656A: This mutation had the most dramatic effect, increasing the $IC_{50}$ by 13-fold for isotonitazene and 73-fold for protonitazene. This highlights F656 as a critical residue for nitazene binding, particularly for protonitazene.
Trafficking: Chronic exposure to isotonitazene or protonitazene did not reduce hERG channel trafficking to the cell surface; in fact, a small increase in surface expression was observed. Thus, the risk is acute inhibition rather than chronic downregulation.
Environmental and Combinatorial Effects:
- Hypokalemia: Reduced extracellular potassium (1 mM) significantly increased the potency of isotonitazene ( $IC_{50}$ dropped to 0.2 $\mu$ M) but had little effect on protonitazene.
- Drug Combinations: Co-administration of fentanyl with either isotonitazene or protonitazene resulted in exacerbated $I_{hERG}$ block compared to either drug alone.
Computational Insights: Docking and MD simulations confirmed that both compounds bind within the pore, interacting with F557, Y652, and F656. Protonitazene adopted a more central, pore-spanning orientation, while isotonitazene favored a pocket-oriented conformation toward F557.

Significance and Claims
The authors claim this study provides the first definitive experimental demonstration that nitazene opioids directly inhibit hERG channels. The findings establish that:

Nitazenes are direct hERG blockers with micromolar and sub-micromolar potency.
The mechanism involves gating-dependent block requiring channel activation and inactivation, with a critical binding interaction involving the F656 residue.
The risk of hERG-mediated cardiotoxicity is acute and can be exacerbated by hypokalemia (specifically for isotonitazene) and by co-ingestion with other hERG-blocking drugs like fentanyl.
While post-mortem concentrations in some fatalities (e.g., protonitazene at ~3.4 $\mu$ M) are sufficient to cause substantial block, the study notes that clinical extrapolation requires caution. However, the data suggest that nitazene use, particularly in combination with other illicit substances or under electrolyte imbalance, presents a plausible risk for QT interval prolongation and arrhythmia, independent of respiratory depression.

The paper concludes that hERG is a direct target for nitazene opioids and that clinicians should be aware of the potential for cardiac electrophysiological effects when treating individuals using these substances, especially in combination with other drugs.

More like this